Scotland, Graham, Royle, Pamela, Henderson, Rob, Hollick, Rosemary, McNamee, Paul and Waugh, Norman (2010) Evidence review : denosumab for the prevention of osteoporotic fractures in post-menopausal women. [Report]

Full text not available from this repository.

Item Type:	Report
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Osteoporosis -- Treatment, Fractures -- Treatment
Publisher:	Aberdeen HTA Group
Place of Publication:	Aberdeen
ISSN:	1366-5278
Date:	2010
Number of Pages:	103
Status:	Not Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Adapted As:	Waugh, N., et al. (2011) Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Health Technology Assessment, Vol.15 (No.S1). pp. 51-59.
Version or Related Resource:	Scotland, G., et al. (2011) Denosumab for the prevention of osteoporotic fractures in post-menopausal women. PharmacoEconomics, Vol.29 (No.11). pp. 951-961
Related URLs:	Related item in WRAP Related item in WRAP
References:	1. National Institute for Health and Clinical Excellence. TA160 Osteoporosis - primary prevention: guidance. 2010, January http://guidance.nice.org.uk/TA160/Guidance/pdf/English (accessed 17 March 2010) 2. National Institute for Health and Clinical Excellence. TA161 Osteoporosis - secondary prevention including strontium ranelate: guidance. 2010, January http://guidance.nice.org.uk/TA161/Guidance/pdf/English (accessed 17 March 2010) 3. U.S.Food and Drug Administration. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs. 13/11/2009, August 13 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM176605.pdf (accessed 17 March 2010) 4. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007;63(9):843-9. 5. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010;95(3):1174-81. 6. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357(18):1799-809. 7. Scottish Medicines Consortium. Zoledronic acid (Aclasta). 2008, March http://www.scottishmedicines.org.uk/smc/5601.html (accessed 22 March 2010) 8. Datamonitor. Pipeline and Commercial Insight:Osteoporosis. 2009, July http://www.datamonitor.com/store/Download/Brochure/?productId=DMHC2511 (accessed 22 March 2010) 9. Scottish Medicines Consortium. Ibandronic acid, 3mg in 3ml solution for injection (Bonviva). 2006, August http://www.scottishmedicines.org.uk/smc/4923.html (accessed 22 March 2010) 10. Scottish Medicines Consortium. Ibandronic acid (Bonviva®). 2006, January http://www.scottishmedicines.org.uk/smc/2336.html (accessed 22 March 2010) 11. Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65. 12. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007;356(18):1809-22. 13. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35(3):488-97. 14. Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 2008;264(4):315-32. 15. Carmona R, Adachi R. Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acid. Patient Prefer Adherence 2009;3:189-93. 16. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18(8):1023-31. 17. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2009. 18. Gold DT, Trinh H, Safi W. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Curr Med Res Opin 2009;25(8):1831-9. 19. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007;82(12):1493-501. 20. Ziller V, Zimmermann SP, Kalder M, Ziller M, Seker-Pektas B, Hellmeyer L et al. Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 2010;26(3):675-81. 21. Bruyere O, Reginster JY. Bone mineral density as a tool to monitor postmenopausal osteoporosis treatment. Medicographia 2008;34(4):355-9. 22. Cefalu CA. Is bone mineral density predictive of fracture risk reduction?. [Review] [53 refs]. Current Medical Research & Opinion 2004;20(3):341-9. 23. Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 2007;41(3):308-17. 24. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy.[see comment]. Bone 2004;34(4):599-604. 25. Small RE. Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed 2005;7(2):3. 26. Kerse N, Parag V, Feigin VL, McNaughton H, Hackett ML, Bennett DA et al. Falls after stroke: results from the Auckland Regional Community Stroke (ARCOS) Study, 2002 to 2003. Stroke 2008;39(6):1890-3. 27. Ramnemark A, Nyberg L, Borssen B, Olsson T, Gustafson Y. Fractures after stroke. Osteoporosis International 1998;8(1):92-5. 28. Dennis MS, Lo KM, McDowall M, West T. Fractures after stroke: frequency, types, and associations. Stroke 2002;33(3):728-34. 29. Myint PK, Poole KE, Warburton EA. Hip fractures after stroke and their prevention. Qjm 2007;100(9):539-45. 30. Poole KE, Loveridge N, Rose CM, Warburton EA, Reeve J. A single infusion of zoledronate prevents bone loss after stroke. Stroke 2007;38(5):1519-25. 31. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50(6):683-91. 32. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147. 33. Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ et al. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial. Chin Med J (Engl ) 2004;117(7):1029-35. 34. Blythe SL. Denosumab, osteoporosis, and prevention of fractures. N Engl J Med 2009;361(22):2189-90. 35. Strom O, Macarios D, Badamgarav E, Borgstrom F, Jonsson B, Tosteson A et al. Cost-Effectiveness Model for Denosumab Incorporating Frax (R) and Adherence in A UK Setting. Osteoporosis International 2009;20(Suppl. 1):20. 36. Hiligsmann M, Reginster JY. Cost-Utility of Denosumab for the Treatment of Postmenopausal Osteoporotic Women. Osteoporosis International 2009;20(Suppl. 1):16. 37. Department of Health. Casemix measures: Healthcare Resource Groups (HRGs). 2006 http://www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/NHSFinancialReforms/DH_4132803 (accessed 22 March 2010) 38. BMJ Group, RPS Publishing. British National Formulary. 2009 http://bnf.org/bnf/ (accessed 17 March 2010) 39. Department of Health. Hospital Episode Statistics (HES). 2010 http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/HospitalEpisodeStatistics/DH_576 (accessed 22 March 2010) 40. Peasgood T, Herrmann K, Kanis JA, Brazier JE. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 2009;20(6):853-68. 41. Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 2008;79(2):269-80. 42. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. Journal of Bone and Mineral Research 2000;15(7):1384-92. 43. Cockerill W, Lunt M, Silman AJ, Cooper C, Lips P, Bhalla AK et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004;15(2):113-9. 44. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. International Journal of Technology Assessment in Health Care 2005;21(2):165-71. 45. Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009;151(10):703-226. 46. Jacobsen DE, Samson MM, Emmelot-Vonk MH, Verhaar HJ. Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause 2010;17(2):309-14. 47. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010;102(5):799-802. 48. Shetty KD, Vogt WB, Bhattacharya J. Hormone replacement therapy and cardiovascular health in the United States. Medical Care 2009;47(5):600-6. 49. Brewster DH, Sharpe KH, Clark DI, Collins J. Declining breast cancer incidence and decreased HRT use. Lancet 2009;373(9662):459-60. 50. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? European Journal of Cancer 2009;45(9):1649-53. 51. Meyer HE, Lofthus CM, Sogaard AJ, Falch JA. Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Osteoporos Int 2009;20(5):827-30. 52. Fisher AA, O'Brien ED, Davis MW. Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 2009;45(2):246-53. 53. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38. 54. Naylor KE, Clowes JA, Finigan J, Paggiosi MA, Peel NF, Eastell R. The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 2010;46(3):592-7. 55. Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 2009;7(1):12-7. 56. Stevenson MD, Oakley JE, Lloyd JM, Brennan A, Compston JE, McCloskey EV et al. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. Med Decis Making 2009;29(6):678-89. 57. Emaus N, Wilsgaard T, Awad L, Grimnes G, Omsland T, Berntsen G. Lifestyle Impact on Lifetime Bone Loss in Women and Men - the Tromso Study. Osteoporosis International 2009;20(Suppl. 1):5-6. 58. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326(7387):469. 59. Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58(6):1687-95. 60. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-68. 61. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282(7):637-45. 62. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13(11):1747-54. 63. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 2003;14(10):793-800. 64. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23(12):1923-34. 65. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8):1241-9. 66. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-41.
URI:	http://wrap.warwick.ac.uk/id/eprint/50157

Request changes to a record

Available Versions of this Item

• Denosumab for the prevention of osteoporotic fractures in post-menopausal women. (deposited 03 May 2012 09:03)
  • Evidence review : denosumab for the prevention of osteoporotic fractures in post-menopausal women. (deposited 03 Oct 2012 13:40) [Currently Displayed]

Actions (login required)

View Item